23Jul 2023
Neoadjuvant chemotherapy enhances tumor‐specific T cell immunity in patients with HPV‐associated oropharyngeal cancer

Neoadjuvant chemotherapy enhances tumor‐specific T cell immunity in patients with HPV‐associated oropharyngeal cancer

Treatment of patients with newly diagnosed HPV‐associated oropharyngeal squamous cell carcinoma (OPSCC) with neoadjuvant chemotherapy (NAC) results in a high rate of 5‐year recurrence-free survival. This study suggests that NAC induces HPV‐specific tumour T cell responses in patients with newly diagnosed HPV‐associated OPSCC, whereas lack of an increase following NAC may associate with the risk of relapse.

  • #ent

Like

Save

Share